On August 21–22, 2026, the Academic Conference of the Perinatal Medicine Branch, hosted by the Ningbo Medical Association, was successfully held. Jiao Mingming, General Manager of Zhejiang Tianyuan Biotechnology Co., Ltd., attended the conference with his team, joining perinatal medicine experts, physicians, and industry peers from the Ningbo region to learn about the latest disciplinary advances and to discuss development trends in maternal and infant health and neonatal medicine.

      The conference aimed to promote disciplinary development and professional advancement in the neonatal field in the Ningbo region, enhance capabilities in disease diagnosis and treatment, and facilitate the learning and exchange of new theories, knowledge, technologies, and methods in perinatal medicine. Centering on topics related to perinatal medicine and neonatal health, the conference provided a high-quality academic exchange platform for professionals in the region and offered fresh perspectives for technological progress and service collaboration in related fields.

      As public health awareness continues to grow, perinatal health management, biological resource storage, and long-term family health planning are attracting increasing attention. Umbilical cord and placenta-derived mesenchymal stem cells are biological resources of significant research value; the standardized collection, preparation, and storage of these cells holds positive significance for life science research and future health management. Through this learning experience, the Tianyuan Biotechnology team gained a deeper understanding of the development direction and practical needs of perinatal medicine, as well as a stronger appreciation of the connections among maternal and infant health, neonatal medicine, and cell resource storage.

      During the conference, Tianyuan Biotechnology's business team participated in learning and exchange with a conscientious and rigorous attitude, further broadening their professional horizons and deepening their understanding of cutting-edge industry information and actual service needs, laying a solid foundation for better business services in the future.

      This participation is of great significance to Tianyuan Biotechnology's future business development. By establishing closer ties with perinatal medicine practitioners, the company has gained a clearer understanding of the current state and development direction of related industries in the Ningbo region, along with valuable references for improving its umbilical cord and placenta stem cell storage system, enhancing team competence, and expanding business scenarios. Meanwhile, the company demonstrated its practical capabilities in cell resource storage and life health through this academic event, helping to expand Tianyuan Biotechnology's brand influence in the Ningbo region and related industries.

      General Manager Jiao Mingming stated that the conference provided the company with a valuable learning opportunity and allowed more industry professionals to further understand Tianyuan Biotechnology's technological foundation and service philosophy. The company will continue to prioritize the professional development of its business team, actively participate in academic activities and industry collaborations, improve its cell resource storage service processes and quality management system, and respond to customer needs with more rigorous, standardized, and professional services.

      Looking ahead, Tianyuan Biotechnology will continue to deepen its focus on life health and cell technology. Building on its technological accumulation and standardized management, the company will strengthen collaboration with medical, scientific research, and related institutions, promote the steady development of its cell resource storage business, and preserve more possibilities for life science research and long-term health management.

Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.